Gene expression inference from cell-free DNA using uncertainty-aware deep learning

Robert D. Patton, A. Patrick McDeed IV, Alexander Netzley, Aditya Pawar, Thomas W. Persse, Akira Nair, Patricia C. Galipeau, Ilsa M. Coleman, Pushpa Itagi, Pooja Chandra, Erolcan Sayar, Mohamed Adil, Manasvita Vashisth, Joseph B. Hiatt, Ruth Dumpit, Lori Kollath, Ridvan Arda Demirci, Alireza Ghodsi, Hung-Ming Lam, Colm Morrissey, Delphine L. Chen, Michael T. Schweizer, Amir Iravani, Andrew C. Hsieh, David MacPherson, Michael C. Haffner, Peter S. Nelson+, Gavin Ha+
bioRxiv Aug 28, 2026, doi:10.64898/2026.02.10.705188 (2026).

Abstract

Tumor gene expression profiling provides crucial diagnostic information for guiding therapy, but standard tissue biopsies are invasive, spatially biased, and may inadequately sample metastatic disease. Cell-free DNA (cfDNA) provides a minimally invasive alternative for tumor genotyping, yet reconstructing robust, transcriptome-wide expression from standard-depth cfDNA whole-genome sequencing (WGS) remains a major challenge. We developed a deep learning framework comprising Triton, for comprehensive cfDNA feature extraction, and Proteus, a probabilistic model that infers single-gene expression from standard-depth cfDNA WGS. Proteus outperformed prior cfDNA approaches in reconstructing molecular phenotypes from matched tumor transcriptomes across multiple cancer types, including prostate, lung, and bladder cancer cohorts, with uncertainty-guided withholding improving model reliability. Proteus further enabled assessment of therapeutic target activity, prognostic transcriptional programs, and candidate treatment-emergent resistance states, establishing a generalizable framework for minimally invasive functional genomics in precision oncology.